Our findings suggest that added dietary leucine significantly decreased intestinal inflammation for up to four weeks, as evident from the fecal MPO activity; however, leucine had no significant effect on DSS-colitis severity and intestinal permeability. The gene discussed is MPO; the disease is colitis.